Table 3.
Detection of ACL and anti-β2GPI autoantibody-positive sera during infliximab treatment
| Number of positive sera | Anti-β2GPI autoantibodiesa | aCL autoantibodiesb | |||
| IgG | IgM | IgG | IgM | ||
| Infliximab, RA (n = 24) | n0 | 0 | 0 | 0 | 0 |
| nt | 2 | 1c | 0 | 5 | |
| Infliximab, AS (n = 15) | n0 | 0 | 0 | 0 | 0 |
| nt | 0 | 2 | 3 | 1 | |
| Control, RA (n = 30) | n0 | 0 | 0 | 0 | 0 |
| nt | 0 | 0 | 0 | 0 | |
Anti-β2GPI, anti-β2-glycoprotein I autoantibodies; aCL, anticardiolipin autoantibodies; n0, number of positive sera before treatment; nt, number of positive sera before treatment plus number of induced autoantibodies during infliximab treatment.
aAnti-β2GPI with one high titer (5.4 AU/ml [IgG], 5 AU/ml [IgM]) and one moderate titer (2.1 AU/ml [IgG]), in 2 of 15 AS with two high titers (8.7 AU/ml [IgG], 3.4 AU/ml [IgM]).
bLow, moderate and high titers were observed in two patients (15.1, 23 G phospholipid), in six patients (22.4, 22.8, 15.4, 21, 22.1 M phospholipid, 27 G phospholipid), and in one patient (41.5 M phospholipid) respectively.
cBoth IgG and IgM.